Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

disease that typically makes weight loss more difficult to achieve.

Changes in secondary endpoints of cardiovascular and metabolic risk were assessed in the Phase 3 program. Body Mass Index (BMI), waist circumference, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, heart rate and quality of life were measured in all three trials in the Phase 3 program, and the integrated Year 1 results showed favorable statistically significant effects with lorcaserin 10 mg BID treatment compared to placebo. Lorcaserin did not increase heart rate or blood pressure; changes from baseline for patients who took lorcaserin 10 mg BID, lorcaserin 10 mg QD or placebo, respectively, were as follows: systolic blood pressure (mmHg), (-0.9, -0.2, -0.2); diastolic blood pressure (mmHg), (-1.4, -0.5, -0.8); and heart rate (bpm), (-1.0, -0.5, -0.2).

The most frequent lorcaserin-associated adverse events included headache, nausea, dizziness, fatigue and dry mouth. Headache was the only adverse event with an incidence that exceeded the placebo group by greater than 5%. In each trial, echocardiograms were performed at baseline and every six months to measure heart valve regurgitation. In the meta-analysis of the three trials, the proportion of patients who developed FDA-defined valvulopathy (moderate or greater mitral insufficiency and/or mild or greater aortic insufficiency) at Week 52 were as follows: lorcaserin 10 mg BID (2.37%), lorcaserin 10 mg QD (1.57%) and placebo (2.04%).

"There is a significant unmet need for effective treatment options that can help patients reduce their weight and improve their health in a well-tolerated manner," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "A diverse group of patients received lorcaserin in our Phase 3 program and achieved clinically meaningful weight loss and improvements in important cardiovascular and metabolic para
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... comprehensive overview of the company,s corporate responsibility efforts. ... approach to corporate responsibility by increasingly leveraging its ... have greater, more sustainable impact. The ... thorough look at the company,s progress on numerous ...
(Date:5/4/2015)... NASHVILLE, Tenn. , May 4, 2015  Verus ... after its acquisition of CPAP Care Club in 2012.  ... CPAP business within the durable medical equipment (DME) industry ... apnea patients for their CPAP supply needs and processes ... we bought this company three years ago, the systems ...
(Date:5/4/2015)... , May 4, 2015 CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... countries worldwide, will report Q1 2015 financial results ... 2015.  CytoSorbents, management will host ... will recount both operational and financial progress during ...
Breaking Medicine Technology:Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4Verus Healthcare Celebrates 1,000% Growth on Third Anniversary 2CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3
... for maintaining a healthy immune systemPURCHASE, N.Y., Jan. 6 ... Cancer (60(5), 643-651) by researchers at Kansai Medical ... Hexose Correlated Compound) enhances immune function by increasing the ... part of the immune system responsible for presenting foreign ...
... 6 Pacira Pharmaceuticals, Inc., an,acute care specialty ... in two pivotal Phase III SIMPLE trials to ... administration of EXPAREL(TM),(DepoBupivacaine) for prolonged postoperative analgesia. , ... in hemorrhoidectomy and in total knee,arthroplasty (TKA) are ...
Cached Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
(Date:5/4/2015)... 2015 In May of 2010, after two ... life. In the wake of this tragedy, Ty’s parents Kirk ... that exposes the grim reality of bullying and its devastating ... Kirk and Laura to share their story and offer education ... to another family — a mission that took the Smalley ...
(Date:5/4/2015)... May 04, 2015 The U.S. healthcare ... boomers join the ranks of senior citizens (1) and ... an already over-burdened healthcare system. Additionally, as older healthcare ... replace them. Per the U.S. Census Bureau, the number ... increase 75% by 2050 while those 25 to 54 ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... . While the World Cup is the most known ... years, the International Champions Cup is one of the biggest ... attendance record for soccer in the United States set when ... the University of Michigan. This year, the defending champion Manchester ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4
... to Demonstrate Single-Agent Activity, - 38% Response Rate, 43% Disease Control ... Refractory Hodgkin Lymphoma ... in 110mg Cohort, ... Including an 18% Response Rate in Evaluable Diffuse Large B- cell ...
... that has saved more than 100,000 lives, now is saving ... disease progression with long term use in adults with chronic ... continues to show how much Gleevec has completely changed the ... Druker, M.D., director of the OHSU Cancer Institute. , ...
... ATLANTA, GA, December 8, 2007 -- Results from two ... with bortezomib provide preliminary anti-tumor activity in patients with ... study showed that 10 of 21 (48 percent) evaluable ... ZOLINZA and bortezomib combination treatment. Data from a ...
... 8, 2007 There is a clear link between GABA ... that inhibits neurons in the brain and ... the American College of Neuropsychopharmacology (ACNP) annual meeting. Researchers ... a finding which could potentially help curb the pleasurable ...
... Boca Raton, FL, December 8, 2007 Bipolar disorder, ... the circadian system the bodys internal clock ... irregularities in the circadian system that can trigger key ... today at the American College of Neuropsychopharmacology (ACNP) annual ...
... Dec. 7 On the heels of today,s,Human ... immigrant,detainees, AIDS Healthcare Foundation (AHF) today criticized the ... disregard for the,health and well-being of people living ... Indifference: HIV/AIDS Services for Immigrants,Detained by the U.S.," ...
Cached Medicine News:Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 7Health News:Gleevec, the targeted cancer pill, delivers more good news to patients 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Studies find stable sleep patterns and regular routines may improve outcomes in bipolar disorder 2Health News:Studies find stable sleep patterns and regular routines may improve outcomes in bipolar disorder 3Health News:Denial of Care for HIV+ Detainees 'Unacceptable,' Says AHF 2
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... Vibrating Mesh Technology to efficiently deliver ... Asthma, COPD or other respiratory conditions. ... and handy carrying case that is ... Powerful delivery comparable to table-top compressor ...
... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
Medicine Products: